Developing a new approach for the treatment of atopic dermatitis in dogs
IMULAN BioTherapeutics, LLC is a privately-owned company developing new immune modulators from our T-Cell Receptor (TCR) peptide platform. IMULAN is in late stage development of a new canine atopic dermatitis treatment using a new, first-in-class immuno-therapeutic (TCR peptides). Dog atopy and allergic dermatitis affect millions of dogs in the United States, and our immunological approach for canine atopy targets the immune cells which trigger dog allergies. We are also designing studies for other diseases including feline stomatitis, FeLV, FIV, and systemic mycosis.